P423 Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
Casellas F.*1, Barreiro-de Acosta M.2, Esteve M.3, Castro-Laria L.4, Vicente R.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Boudet J.M.5, Rodríguez-San Pedro L.13, Díaz G.13, Casado R.13, Marín I.14
1Hospital Universitari Vall Hebron, Barcelona, Spain, Barcelona, Spain 2Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain 3Hospital Universitari Mutua Terrassa, Barcelona, Spain 4Hospitales Universitarios Virgen Macarena-Rocío, Sevilla, Spain 5Hospital Universitario Miguel Servet, Zaragoza, Spain 6Dr. Negrin University Hospital, Las Palmas, Spain 7Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain 8Hospital Universitario la Paz, Madrid, Spain 9Hospital Universitari Dr. Josep Trueta, Girona, Spain 10Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 11Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain 12Hospital General Universitario de Valencia, Valencia, Spain 13Abbvie, Madrid, Spain 14Hospital Universitario Gregorio Marañόn, Madrid, Spain
Clinical response and patient's quality of life improve as a result of the direct benefit of Crohn's disease (CD) effective treatment. Rapidity of response to treatment in CD is a field of major interest, due to the importance of achieving the highest benefit in the shortest possible time.
There are no studies specifically designed for early evaluation of the quality of life in patients with active CD receiving adalimumab therapy.
The aim of this study was to evaluate the rapidity of improvement of quality of life in response to adalimumab therapy in adult antiTNF naïve patients with active luminal (Harvey-Bradshaw Index ≥8) moderate-to-severe CD, and with no response to a full and adequate course of therapy with corticosteroids and/or immunosuppressants.
To this purpose we designed aninterventional, prospective, open label, single arm and multicenter clinical trial. Quality of life was evaluated by using the validated questionnaires EuroQol-5D (EQ-5D) and the 36 items version of the Inflammatory Bowel Disease Questionnaire (IBDQ-36). Questionnaires were administered at baseline, day 4 and weeks 1, 2 4 and 12 with standardized adalimumab treatment (160 mg – 80 mg – 40 mg eow).
The modified intention to treat (mITT) population was the primary population for analysis and consisted of those patients enrolled in the study who had received at least one dose of adalimumab.
Statistical analyses were performed by the t-test or the Wilcoxon signed rank test, as applicable.
Eighty patients were included. At baseline, the median EQ-5D index score was 0.68. EQ-5D scores improved significantly versus baseline, at day 4 and weeks 1, 2, 4 and 12, with median changes of 0.05 (p<0.01), 0.05 (p<0.001), 0.11 (p<0.001), 0.10 (p<0.001) and 0.12 (p<0.001), respectively. Similarly, EQ-5D VAS median scores also improved significantly, compared to baseline (median score at baseline: 55.00), at day 4 and thereafter, with median changes of 6.00, 5.00, 10.00, 10.00 and 13.00, respectively (p<0.001 at all time-points).
The comparison, versus baseline, of the IBDQ-36 overall score (median score at baseline: 143.50) at day 4 and weeks 1, 2, 4 and 12, also yielded statistically significant differences, with median improvements of 14.0, 18.0, 30.0, 42.0 and 32.0 respectively (p<0.001 at all time-points). Restoration of normal health (IBDQ-36 score >209) was obtained in 11% of patients at day 4 and increased to 31% at week 12.
Adalimumab produces rapid improvement of quality of life since day 4 in patients with moderate-to-severe Crohn's disease.